EFIRM Liquid Biopsy (eLB)
Who's speaking at this Webinar?
Director, Center for Oral/Head & Neck Oncology Research
advent of personalized medicine employing molecular targeted therapies
has markedly changed the treatment of cancer in the past decade. Liquid
biopsy is a rapidly emerging field to address this unmet clinical need
as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a
surrogate for the entire tumor genome.
We have developed a liquid biopsy technology “Electric Field Induced
Release and Measurement (EFIRM)- Liquid Biopsy (eLB)” provides the most
accurate targeted detection that can assist clinical treatment decisions
for the most common subtype of lung cancer, non-small cell lung cancer
(NSCLC), where tyrosine kinase inhibitors (TKI) that can extend the
disease progress free survival period of these patients.
Attend this webinar to learn:
- Liquid biopsy for cancer detection
- Electric field induced released and measurement (EFIRM)
- Saliva as a sample type for liquid biopsy